Journal of Clinical Oncology (JCO) Podcast
by American Society of Clinical Oncology (ASCO)
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 15 chart positions in 15 markets.
By chart position
- 🇬🇧GB · Medicine#1155K to 30K
- 🇨🇦CA · Medicine#1825K to 30K
- 🇰🇷KR · Medicine#5810K to 30K
- 🇯🇵JP · Medicine#1951K to 10K
- 🇸🇦SA · Medicine#2210K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
23K to 94K🎙 ~2x weekly·454 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
46K to 187K🇬🇧16%🇨🇦16%🇰🇷16%+12 more - Active Followers
Loyal subscribers who consistently listen
14K to 56K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHosts
Recent guests
Recent episodes
Effectiveness of a Virtual Tobacco Treatment for Cancer Patients
Jul 16, 2026
24m 21s
Phase 2 Study of Multi-Cancer Detection from Breath Samples
Jun 11, 2026
20m 18s
JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
Jun 1, 2026
10m 28s
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
Jun 1, 2026
12m 05s
JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS
May 31, 2026
11m 19s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/16/26 | tobacco cessationcancer treatment+3 | Dr. Elise ParkDr. Jamie Ostrov | American Society of Clinical OncologyNCI Community Oncology Research Program+1 | — | tobacco treatmentcancer patients+4 | — | 24m 21s | ||
| 6/11/26 | multi-cancer detectionbreath samples+4 | Akash KulgodDr. Sanjeev Kulgod | Canine Olfaction Combined with Bayesian Modeling for Multi Cancer Detection from Breath Samples, a Phase 2 Study in India | — | multi-cancer detectionbreath samples+5 | — | 20m 18s | ||
| 6/1/26 | neoantigen therapymelanoma+3 | Dr. Grant McArthur | American Society of Clinical OncologyIntismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study | — | neoantigen therapypembrolizumab+5 | — | 10m 28s | ||
| 6/1/26 | CholangiocarcinomaPemigatinib+3 | Dr. Eileen M. O'Reilly | American Society of Clinical OncologyPemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial | — | CholangiocarcinomaPemigatinib+5 | — | 12m 05s | ||
| 5/31/26 | breast cancertamoxifen+3 | Dr. Yuvanesh VedarajuDr. Kathy Miller | American Society of Clinical OncologyLow-Dose Tamoxifen in Non-Invasive Breast Neoplasia: Long-Term Results from an Individual Participant Data Pooled Analysis | — | low-dose tamoxifenDCIS+3 | — | 11m 19s | ||
| 5/31/26 | neoadjuvant therapymuscle-invasive bladder cancer+3 | Dr. Jake NewDr. Umang Swami | American Society of Clinical OncologyNeoadjuvant Sacituzumab Govitecan in Patients with Muscle-Invasive Bladder Cancer: Primary Results of SURE-01 Trial | — | neoadjuvant therapysacituzumab+3 | — | 8m 56s | ||
| 5/29/26 | intravesical therapychemo-immunotherapy+3 | Dr. Jake NewDr. Andrea Necchi | American Society of Clinical OncologyAddition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single Arm Phase 2 Trial SAKK 06/19 | — | intravesical BCGchemo-immunotherapy+3 | — | 13m 08s | ||
| 5/14/26 | adjuvant therapyimmunotherapy+4 | Dr. Glenwood Goss | Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer | — | DurvalumabNSCLC+4 | — | 20m 04s | ||
| 4/27/26 | head and neck cancerrecurrent cancer+4 | — | American Society of Clinical OncologyLicitra et al.+1 | — | LEAP-010head and neck squamous cell carcinoma+4 | — | 10m 41s | ||
| 4/9/26 | diet strategieshematopoietic stem cell transplant+3 | Dr. John Wingard | American Society of Clinical OncologyRandomized Non-inferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem Cell Transplant and Acute Leukemia Patients | — | infectionsdiet strategies+6 | — | 20m 40s |
Showing 10 of 10
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for Journal of Clinical Oncology (JCO) Podcast
Peaked at #22 in SA, currently #22 in SA.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| SA | — | #22 | #22 | — |
| VN | — | #38 | #38 | — |
| South Korea | — | #58 | #58 | — |
| SA | — | #99 | #99 | — |
| PE | — | #107 | #107 | — |
| United Kingdom | — | #115 | #115 | — |
| MY | — | #116 | #116 | — |
| TW | — | #121 | #121 | — |
| PL | — | #131 | #131 | — |
| HK | — | #136 | #136 | — |
| TR | — | #163 | #163 | — |
| SG | — | #168 | #168 | — |
| RO | — | #179 | #179 | — |
| Canada | — | #182 | #182 | — |
| CL | — | #190 | #190 | — |
| Japan | — | #195 | #195 | — |
Chart Positions
16 placements across 15 markets.
Chart Positions
16 placements across 15 markets.